牛牛AI助理已提取核心訊息
On January 4, 2024, Walgreens Boots Alliance, Inc. (WBA) reported its financial results for the first fiscal quarter ending November 30, 2023. The company announced a net loss of $67 million, a significant improvement from the $3.7 billion net loss in the previous year's quarter. This improvement was primarily due to the absence of a $6.5 billion pre-tax charge for opioid-related claims and litigation recorded in the year-ago quarter. Despite the net loss, WBA saw a 10% increase in sales year-over-year, reaching $36.7 billion. The adjusted earnings per share (EPS) decreased by 43.1% to $0.66, influenced by challenging retail market trends in the U.S. and a higher tax rate. WBA also declared a 48% reduction in its quarterly dividend payment to $0.25 per share. The company...Show More
On January 4, 2024, Walgreens Boots Alliance, Inc. (WBA) reported its financial results for the first fiscal quarter ending November 30, 2023. The company announced a net loss of $67 million, a significant improvement from the $3.7 billion net loss in the previous year's quarter. This improvement was primarily due to the absence of a $6.5 billion pre-tax charge for opioid-related claims and litigation recorded in the year-ago quarter. Despite the net loss, WBA saw a 10% increase in sales year-over-year, reaching $36.7 billion. The adjusted earnings per share (EPS) decreased by 43.1% to $0.66, influenced by challenging retail market trends in the U.S. and a higher tax rate. WBA also declared a 48% reduction in its quarterly dividend payment to $0.25 per share. The company maintained its fiscal 2024 adjusted EPS guidance of $3.20 to $3.50, expecting underlying earnings growth to be offset by various factors including a higher tax rate and lower COVID-19 contributions. The U.S. Healthcare segment reported a sales increase to $1.9 billion, with VillageMD and Shields driving growth. The U.S. Retail Pharmacy segment saw a 6.4% increase in sales, while the International segment's sales rose by 12.4%. WBA's CEO Tim Wentworth emphasized the company's focus on strategic options to drive long-term shareholder value, cost management, and cash flow improvement.
2024年1月4日,Walgreens Boots Alliance, Inc.(WBA)公佈了截至2023年11月30日的第一財季財務業績。該公司宣佈淨虧損6700萬美元,與去年同期的37億美元淨虧損相比有了顯著改善。這種改善主要是由於去年同期記錄的與阿片類藥物相關的索賠和訴訟沒有65億美元的稅前費用。儘管出現淨虧損,但WBA的銷售額同比增長了10%,達到367億美元。受美國零售市場充滿挑戰的趨勢和更高的稅率的影響,調整後的每股收益(EPS)下降了43.1%,至0.66美元。WBA還宣佈將季度股息支付減少48%,至每股0.25美元。該公司維持其2024財年調整後的每股收益預期爲3.20美元至...展開全部
2024年1月4日,Walgreens Boots Alliance, Inc.(WBA)公佈了截至2023年11月30日的第一財季財務業績。該公司宣佈淨虧損6700萬美元,與去年同期的37億美元淨虧損相比有了顯著改善。這種改善主要是由於去年同期記錄的與阿片類藥物相關的索賠和訴訟沒有65億美元的稅前費用。儘管出現淨虧損,但WBA的銷售額同比增長了10%,達到367億美元。受美國零售市場充滿挑戰的趨勢和更高的稅率的影響,調整後的每股收益(EPS)下降了43.1%,至0.66美元。WBA還宣佈將季度股息支付減少48%,至每股0.25美元。該公司維持其2024財年調整後的每股收益預期爲3.20美元至3.50美元,預計基礎收益增長將被包括更高稅率和 COVID-19 繳款減少在內的各種因素所抵消。美國醫療保健板塊報告銷售額增長至19億美元,VillageMD和Shields推動了增長。美國零售藥房板塊的銷售額增長了6.4%,而國際板塊的銷售額增長了12.4%。WBA首席執行官蒂姆·溫特沃斯強調了公司專注於戰略選擇,以推動長期股東價值、成本管理和現金流改善。
有用
沒用